9gtl

Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with iminosugar compound 4j

spinqualitylabelsall models 9gtl, resolution 2.00Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 9gtl is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 2Å Ligands: A1IO9, BMA, CL, CSO, EDO, FUC, GOL, MAN, NAG, PEG, PGE, SO4 Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Disease LYAG_HUMAN Glycogen storage disease due to acid maltase deficiency, infantile onset;Glycogen storage disease due to acid maltase deficiency, juvenile onset;Glycogen storage disease due to acid maltase deficiency, adult onset. The disease is caused by mutations affecting the gene represented in this entry. Function LYAG_HUMAN Essential for the degradation of glygogen to glucose in lysosomes. Publication Abstract from PubMed We report herein the design and synthesis of a series of 5-C-alkyldeoxynojirimycins from l-sorbose, through an efficient and scalable method amenable to preparing a large variety of analogues. The interaction of this class of compounds with human acid alpha-glucosidase (GAA), the genetically defective enzyme in patients suffering from Pompe disease, was investigated to identify pharmacological chaperones exhibiting high selectivity for this enzyme. Crystallographic analyses provided a rationale for their binding mode to GAA and chaperone activity. The effects of 5-C-phenethyl-DNJ (4c) were evaluated on GAA activity enhancement in cells from Pompe disease patients and in vivo in GAA-KO mice. The significant increase of GAA activity in the presence of 4c in various tissues, particularly in the diaphragm, encourages further studies on this class of small molecules toward developing clinical drugs. Their chaperone activity and excellent selectivity may offer potential benefits over the current treatments for Pompe disease. C-Branched Iminosugars as Selective Pharmacological Chaperones of Lysosomal alpha-Glucosidase for the Treatment of Pompe Disease.,Vieira Da Cruz A, Perraudin V, Minopoli N, Iacono R, Roig-Zamboni V, Bossio A, Tangara S, Fayolle M, Kanazawa A, Philouze C, Tarallo A, Heming JJA, Artola M, Behr JB, Overkleeft HS, Moracci M, Sulzenbacher G, Parenti G, Py S J Med Chem. 2025 Sep 25;68(18):19269-19286. doi: 10.1021/acs.jmedchem.5c01349. , Epub 2025 Sep 15. PMID:40951993 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Proteopedia Page Contributors and Editors (what is this?)

OCA